Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | CTSL | P07711 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16118654 | 0.85 | KMT2A (0.51) | KMT2ALMNAALDH1A1MAPTHDAC3 | |
| SCHEMBL16118659 | 0.85 | KMT2A (0.51) | KMT2ALMNAALDH1A1MAPTHDAC3 | |
| SCHEMBL16118661 | 0.79 | POLB (0.44) | KMT2ALMNAALDH1A1 | |
| SCHEMBL16118643 | 0.68 | LMNA (0.53) | KMT2ALMNAALDH1A1HDAC1HDAC6 | |
| SCHEMBL4321271 | 0.65 | CHRM1 (0.42) | KMT2ASLC6A4 | |
| SCHEMBL4321273 | 0.65 | CHRM1 (0.42) | KMT2ASLC6A4 | |
| SCHEMBL13102668 | 0.65 | MAPK1 (0.43) | ALDH1A1HDAC1MAPK1CTSLOPRL1 | |
| SCHEMBL7901967 | 0.65 | MAPK1 (0.43) | ALDH1A1HDAC1MAPK1CTSLOPRL1 | |
| SCHEMBL16118645 | 0.64 | MLNR (0.42) | KMT2ALMNAALDH1A1HPGDHDAC1 | |
| SCHEMBL16118649 | 0.63 | NPC1 (0.44) | KMT2ALMNAHDAC3HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9796674-B2 | Benzyl urea derivatives for activating TGF-beta signaling | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2017-10-24 | — | — | US | disclosed |
| US-9796674-B2 | Benzyl urea derivatives for activating TGF-beta signaling | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2017-10-24 | — | — | US | disclosed |
| US-20160039756-A1 | BENZYL UREA DERIVATIVES FOR ACTIVATING TGF-BETA SIGNALING | The Board of Trustees of the Leladn Stanford Junior University (US) | 2016-02-11 | — | — | US | disclosed |
| US-20160039756-A1 | BENZYL UREA DERIVATIVES FOR ACTIVATING TGF-BETA SIGNALING | The Board of Trustees of the Leladn Stanford Junior University (US) | 2016-02-11 | — | — | US | disclosed |
| WO-2014152869-A2 | BENZYL UREA DERIVATIVES FOR ACTIVATING TGF-BETA SIGNALING | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2014-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160039756-A1 | BENZYL UREA DERIVATIVES FOR ACTIVATING TGF-BETA SIGNALING | TGFBR1, TGFB1, TGFBR2 | KMT2A 2008/4885LMNA 1092/4885ALDH1A1 3206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.